Subgroup meta-analyses based on participants kidney function indicated that the salutary effects of SGLT2i on MACE, cardiovascular death or HHF, and a composite kidney outcome (substantial loss of kidney function, end-stage kidney disease or death due to kidney disease) do not significantly differ among subgroups based on eGFR [142, 252]
Here is the math, broken down for every common concentration you will encounter with compounded semaglutide
While you are taking Ozempic, its advisable to limit or avoid alcoholic beverages
Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al
Treatment for kidney disease The positive results from FLOW demonstrate[d] the potential for semaglutide to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease, Lange said at the time study results were released